Posted by Michael Wonder on 16 Mar 2021
AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442
16 March 2021 - Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment.
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody combination which is in late-stage development for the prevention and treatment of COVID-19.
